Evidence map›Paper›PMID 39412961›Full record

ArticleHead & neck2025

Sinonasal Squamous Cell Carcinoma in the Netherlands: A Population-Based Study of 568 Cases Diagnosed in 2008-2021.

Lise J van de Velde, W F Julius Scheurleer, W Weibel Braunius, Caroline M Speksnijder, Mischa de Ridder, Lot A Devriese, Remco de Bree, Gerben E Breimer, Johannes A Rijken, Boukje A C van Dijk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lise J van de VeldeDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0009-0003-9605-1776
W F Julius ScheurleerDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
W Weibel BrauniusDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Caroline M SpeksnijderDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Mischa de RidderDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-2530-3038
Lot A DevrieseUniversity Medical Center Utrecht, Department of Medical Oncology, Utrecht, The Netherlands.
Remco de BreeDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0001-7128-5814
Gerben E BreimerDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Johannes A RijkenDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Boukje A C van DijkDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSinonasal squamous cell carcinoma is known for its rarity and poor prognosis. This study aims to investigate the trends in the incidence of sinonasal squamous cell carcinoma in the Netherlands and to analyze patient characteristics and treatment practices in order to assess their relation with patient outcomes.

methodsIn this prospectively designed population-based cohort study, all patients diagnosed with sinonasal squamous cell carcinoma between 2008 and 2021 in the Netherlands were included. Patients with a squamous cell carcinoma of the nasal vestibule were excluded, leading to a definitive study population of 568 cases.

resultsThe annual incidence rate for the overall population displayed a slight upward trend over the inclusion period with an annual percentage change of 1.6%. The 5-year overall, disease-free, and relative survival were 43.0%, 52.0%, and 47.2%, respectively. Relative survival decreased marginally over the course of the inclusion period.

conclusionSinonasal squamous cell carcinoma is rare with approximately stable incidence rates. There is a limited, non-statistically significant, decrease in survival between 2008 and 2021. Therefore, there is a clear need for innovative treatment approaches to improve outcomes for patients with sinonasal squamous cell carcinoma.

Indexed as

Carcinoma, Squamous CellParanasal Sinus NeoplasmsAdultAgedAged, 80 and overCohort StudiesFemaleHumansIncidenceMaleMiddle AgedNetherlandsProspective StudiesSurvival Ratehead and neck cancernose cancerparanasal sinus cancersinonasal cancersquamous cell carcinoma

Identifiers

PMID39412961
PMCPMC11717970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.